Bitetti Teresa Marie 4
4 · TAKEDA PHARMACEUTICAL CO LTD · Filed Apr 28, 2026
Research Summary
AI-generated summary of this filing
Takeda (TAK) President Teresa Bitetti Receives RSU Award
What Happened
Teresa Marie Bitetti, President of the Oncology Business Unit (OBU) at Takeda Pharmaceutical (TAK), was granted 64,988 restricted stock units (RSUs) on April 27, 2026. The Form 4 reports the award with a reported acquisition price of $0 because the RSUs are performance-based and contingent on achievement of specified metrics (core revenue, core operating profit, and R&D milestones). The Compensation Committee determined the final number of RSUs on April 27, 2026 based on those metrics; no cash changed hands at grant.
Key Details
- Transaction date: 2026-04-27; Transaction type: Award/Grant (code A).
- Amount: 64,988 RSUs; reported price/value at grant: $0.
- The filing notes she also has 150,790 RSUs referenced in the report. Vesting schedule for those RSUs: July 1, 2026 (105,044), July 1, 2027 (30,564) and July 1, 2028 (15,182).
- Footnote: Original award was granted July 1, 2023 and became payable based on performance metrics; the Committee determined the payout amount on 2026-04-27.
- Timeliness: Report filed 2026-04-28 for a 2026-04-27 transaction — appears timely.
Context
RSUs are a form of compensation giving the holder a contingent right to receive American Depositary Shares (ADS) if performance conditions and vesting schedules are met. Because this is a compensation award (not an open-market purchase or sale), it should be viewed as part of standard executive pay and not a direct buy/sell signal about near-term insider sentiment.
Insider Transaction Report
- Award
American Depositary Shares
[F1][F2]2026-04-27+64,988→ 258,136 total
Footnotes (2)
- [F1]On July 1, 2023, the reporting person was granted an award of restricted stock units (RSUs), which vest in the form of American Depositary Shares based upon the achievement of the specified performance metrics, including core revenue, core operating profit, and important R&D milestones. On April 27, 2026, the Compensation Committee of the Board of Directors determined the number of RSUs to be awarded based on these performance metrics, which amount is reported above.
- [F2]Includes 150,790 restricted stock units (RSUs). Each RSU represents a contingent right to receive one American Depositary Share. The RSUs vest on the following schedule: July 1, 2026 (105,044 shares), July 1, 2027 (30,564 shares) and July 1, 2028 (15,182 shares).